Drugs & Aging

, Volume 18, Issue 2, pp 87–99 | Cite as

The Clinical Potential of Matrix Metalloproteinase Inhibitors in the Rheumatic Disorders

  • Sarah Elliott
  • Tim Cawston
Leading Article


Rheumatoid arthritis (RA) and osteoarthritis are chronic diseases that result in cartilage degradation and loss of joint function. Currently available drugs are predominantly directed towards the control of pain and/or the inflammation associated with joint synovitis but they do little to reduce joint destruction. In the future, it will be important to have drugs that prevent the structural damage caused by bone and cartilage breakdown.

In this review, we will outline the structure and function of cartilage and the key features of matrix metalloproteinases (MMPs), enzymes involved in joint destruction. We will present evidence for the role of MMPs in RA and osteoarthritis, and describe the potential of synthetic inhibitors to control MMP activity and so prevent joint destruction.

MMPs are able to cleave all components of the cartilage matrix. Regulation of MMPs is aberrant in osteoarthritis and RA, and MMPs have been implicated in the collagen breakdown that contributes to joint destruction in these diseases. Synthetic MMP inhibitors have been developed. In animal models of osteoarthritis and/or RA, these agents have shown chondroprotective effects. However, results from clinical trials in RA have been equivocal, with some studies being terminated because of lack of efficacy or safety concerns. Nevertheless, this approach remains promising. Increased understanding of the structure, regulation and function of individual MMPs may lead to more effective strategies, and approaches aimed at multiple steps of the pathogenesis of arthritis may be needed to break the chronic cycle of joint destruction.


Rheumatoid Arthritis Tace Joint Destruction Marimastat Tenidap 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Conaghan PG, Brooks P. Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine. Curr Opin Rheumatol 1995; 7(3): 167–73PubMedCrossRefGoogle Scholar
  2. 2.
    Hardingham TE, Fosang AJ. Proteoglycans: many forms and any functions. FASEB J 1992; 6: 861–70PubMedGoogle Scholar
  3. 3.
    Muir H. The chondrocyte, architect of cartilage: biomechanics, structure, function and molecular biology of cartilage matrix macromolecules. Bioessays 1995; 17: 1039–48PubMedCrossRefGoogle Scholar
  4. 4.
    Dingle JT, Page TDP, King B, et al. In vivo studies of articular tissue damage mediated by catabolin/interleukin 1. Ann Rheum Dis 1987; 46: 527–33PubMedCrossRefGoogle Scholar
  5. 5.
    Page-Thomas DP, King B, Stephens T, et al. In vivo studies of cartilage regeneration after damage induced by catabolin/interleukin-1. Ann Rheum Dis 1991; 50: 75–80PubMedCrossRefGoogle Scholar
  6. 6.
    Fell HB, Barratt ME, Welland H, et al. The capacity of pig articular cartilage in organ culture to regenerate after breakdown induced by complement-sufficient antiserum to pig erythrocytes. Calcif Tissue Res 1976; 20(1): 3–21PubMedCrossRefGoogle Scholar
  7. 7.
    van der Rest M, Garrone R. Collagen family of proteins. FASEB J 1991; 5(13): 2814–23PubMedGoogle Scholar
  8. 8.
    Jubb RW, Fell HB. The breakdown of collagen by chondrocytes. J Pathol 1980; 130: 159–62PubMedCrossRefGoogle Scholar
  9. 9.
    Cawston TE. Proteinases and inhibitors. Br Med Bull 1995; 51: 385–401PubMedGoogle Scholar
  10. 10.
    Birkedal-Hansen H, Moore WGI, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197–250PubMedGoogle Scholar
  11. 11.
    Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 1990; 87: 5578–82PubMedCrossRefGoogle Scholar
  12. 12.
    Henriet P, Blavier L, DeClerck YA. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS 1999; 107: 111–9PubMedCrossRefGoogle Scholar
  13. 13.
    Collier IE, Wilhelm SM, Eisen AZ, et al. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 1988; 263(14): 6579–87PubMedGoogle Scholar
  14. 14.
    Wilhelm SM, Collier IE, Marmer BL, et al. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989; 264(29): 17213–21PubMedGoogle Scholar
  15. 15.
    Allan JA, Docherty AJP, Barker PJ, et al. Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J 1995; 309: 299–306PubMedGoogle Scholar
  16. 16.
    Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61–5PubMedCrossRefGoogle Scholar
  17. 17.
    Sato H, Kinoshita T, Takino T, et al. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TTMP)-2. FEBS Lett 1996; 393(1): 101–4PubMedCrossRefGoogle Scholar
  18. 18.
    Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995; 375(6528): 244–7PubMedCrossRefGoogle Scholar
  19. 19.
    Matrisian LM. The matrix-degrading metalloproteinases. Bioessays 1992; 14: 455–63PubMedCrossRefGoogle Scholar
  20. 20.
    Clark IM, Rowan A, Cawston TE. Matrix metalloproteinase inhibitors in the treatment of arthritis. Curr Opin Anti-inflamm Immunomod Invest Drugs 2000; 2(1): 16–25Google Scholar
  21. 21.
    Shingleton WD, Hodges DJ, Brick P, et al. Collagenase: a key enzyme in collagen turnover. Biochem Cell Biol 1996; 74(6): 759–75PubMedCrossRefGoogle Scholar
  22. 22.
    Welgus HG, Jeffrey JJ, Stricklin GP, et al. Characteristics of the action of human skin fibroblast collagenase on fibrillar collagen. J Biol Chem 1980; 255(14): 6806–13PubMedGoogle Scholar
  23. 23.
    Hasty KA, Jeffrey JJ, Hibbs MS, et al. The collagen substrate specificity of human neutrophil collagenase. J Biol Chem 1987; 262(21): 10048–52PubMedGoogle Scholar
  24. 24.
    Knauper V, Lopez-Otin C, Smith B, et al. Biochemical characterisation of human collagenase-3. J Biol Chem 1996; 271: 1544–50PubMedCrossRefGoogle Scholar
  25. 25.
    Cawston TE, Rowan AD. Prevention of cartilage breakdown by matrix metalloproteinase inhibition: a realistic therapeutic target? Br J Rheumatol 1998; 37: 353–6PubMedCrossRefGoogle Scholar
  26. 26.
    Clark IM, Powell LK, Ramsey S, et al. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1993; 36: 372–9PubMedCrossRefGoogle Scholar
  27. 27.
    Mort JS, Dodge GR, Roughley PJ, et al. Direct evidence for active metalloproteinases mediating matrix degradation in interleukin 1-stimulated human articular cartilage. Matrix 1993; 13(2): 95–102PubMedCrossRefGoogle Scholar
  28. 28.
    Dodge GR, Pidoux I, Poole AR. The degradation of type II collagen in rheumatoid arthritis: an immunoelectron microscopic study. Matrix 1991; 11(5): 330–8PubMedCrossRefGoogle Scholar
  29. 29.
    McCachren SS. Expression of metalloproteinases and metalloproteinase inhibitor in human arthritic synovium. Arthritis Rheum 1991; 34(9): 1085–93PubMedCrossRefGoogle Scholar
  30. 30.
    Brinckerhoff CE. Joint destruction in arthritis: metalloproteinases in the spotlight. Arthritis Rheum 1991; 34(9): 1073–5PubMedCrossRefGoogle Scholar
  31. 31.
    Arner EC, Pratta MA, Trzaskos JM, et al. Generation and characterization of aggrecanase — a soluble, cartilage-derived aggrecan-degrading activity. J Biol Chem 1999; 274(10): 6594–601PubMedCrossRefGoogle Scholar
  32. 32.
    Abbaszade I, Liu RQ, Yang F, et al. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem 1999; 274(33): 23443–50PubMedCrossRefGoogle Scholar
  33. 33.
    Billington CJ, Clark IM, Cawston TE. An aggrecan-degrading activity associated with chondrocyte membranes. Biochem J 1998; 336(1): 207–12PubMedGoogle Scholar
  34. 34.
    Amour A, Slocombe PM, Webster A, et al. TNF-α converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998; 435(1): 39–44PubMedCrossRefGoogle Scholar
  35. 35.
    Brennan FM, Browne KA, Green PA, et al. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-a (cA2) therapy. Br J Rheumatol 1997; 36(6): 643–50PubMedCrossRefGoogle Scholar
  36. 36.
    Lipsky P, St. Clair W, Furst D, et al. 54 week clinical and radiographic results from the ATTRACT trial: a phase III study of infliximab (Remicade™) in patients with active RA despite methotrexate [abstract]. Arthritis Rheum 1999; 42Suppl. 11: S401Google Scholar
  37. 37.
    Elliott S, Rowan A, Carrère S, et al. Esculetin inhibits cartilage resorption induced by IL-1 α in combination with OSM. Ann Rheum Dis 2001; 60: 158–65PubMedCrossRefGoogle Scholar
  38. 38.
    Martel-Pelletier J, Mineau F, Tardif G, et al. Tenidap reduces the level of interleukin 1 receptors and collagenase expression in human arthritic synovial fibroblasts. J Rheumatol 1996; 23: 24–31PubMedGoogle Scholar
  39. 39.
    Beckett RP, Davidson AH, Drummond AH, et al. Recent advances in matrix metalloproteinase inhibitor research. Drug Disc Today 1995; 1: 16–26CrossRefGoogle Scholar
  40. 40.
    Bottomley KM, Johnson WH, Walter DS. Matrix metalloproteinase inhibitors in arthritis. J Enzyme Inhib 1998; 13(2): 79–101PubMedCrossRefGoogle Scholar
  41. 41.
    Martel-Pelletier, Pelletier JP. Wanted: the collagenase responsible for the destruction of the collage network in human cartilage. Br J Rheumatol 1996; 35(9): 818–20PubMedCrossRefGoogle Scholar
  42. 42.
    Nemunaitis J, Poole C, Primrose J, et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 1998; 4(5): 1101–9PubMedGoogle Scholar
  43. 43.
    Shapiro SD. Mighty mice: transgenic technology ‘knocks out’ questions of metalloproteinase function. Matrix Biol 1997; 15: 527–33PubMedCrossRefGoogle Scholar
  44. 44.
    Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385(6618): 729–33PubMedCrossRefGoogle Scholar
  45. 45.
    Konttinen YT, Ceponis A, Takagi M, et al. New collagenolytic enzymes cascade identified at the pannus-hard tissue junction in rheumatoid arthritis: destruction from above. Matrix Biol 1998; 17(8–9): 585–601PubMedCrossRefGoogle Scholar
  46. 46.
    Knauper V, Will H, Lopez-Otin C, et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation: evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 1996; 271(29): 17124–31PubMedCrossRefGoogle Scholar
  47. 47.
    Brewster M, Lewis EJ, Wilson KL, et al. Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum 1998; 41(9): 1639–44PubMedCrossRefGoogle Scholar
  48. 48.
    Greenwald RA. Treatment of destructive arthritic disorders with MMP inhibitors: potential role of tetracyclines. Ann NY Acad Sci 1994; 732: 181–98PubMedCrossRefGoogle Scholar
  49. 49.
    Greenwald RA, Golub LM, Ramamurthy NS, et al. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation. Bone 1998; 22(1): 33–8PubMedCrossRefGoogle Scholar
  50. 50.
    Cawston TE. Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol Ther 1996; 70(3): 163–82PubMedCrossRefGoogle Scholar
  51. 51.
    Shaw, T. Inhibition of matrix metalloproteinases in rheumatoid arthritis. In: Firestein GS, Panayi GS, Wollheim F, editors. Rheumatoid arthritis. Oxford: Oxford University Press, 2000: 551–61Google Scholar
  52. 52.
    Butler GS, Hutton M, Wattam BA, et al. The specificity of TIMP-2 for matrix metalloproteinases can be modified by single amino acid mutations. J Biol Chem 1992; 274(29): 20391–6CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Sarah Elliott
    • 1
  • Tim Cawston
    • 1
  1. 1.Department of RheumatologyUniversity of NewcastleNewcastle-upon-TyneEngland

Personalised recommendations